Retatrutide

Retatrutide is a synthetic peptide engineered to act as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is designed to engage these three receptor pathways simultaneously, making it distinct from single- and dual-receptor peptide analogs. Retatrutide has been the subject of ongoing scientific investigation to evaluate its pharmacological properties, receptor activity, pharmacokinetics, and physiological interactions. Current research focuses on characterizing its mechanism of action, receptor binding profile, and biological effects in controlled laboratory and clinical study settings.